Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.7.11.24 (
mitogen-activated protein kinase
)
95,810
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Stimulation of Rat-1 fibroblasts, stably transfected with alpha 2C10 receptors, with the specific alpha 2 agonist UK14304 led to the tyrosine phosphorylation and activation of the p42 and p44 isoforms of
MAP kinase
. Tyrosine phosphorylation of the
MAP
kinases was prevented by pertussis toxin. In unstimulated cells, there was constitutive tyrosine phosphorylation and activation of the p44 but not the p42
MAP kinase
. This effect was not seen in non-transfected parental Rat-1 fibroblasts.
...
PMID:Regulation of p42 and p44 MAP kinase isoforms in Rat-1 fibroblasts stably transfected with alpha 2C10 adrenoreceptors. 751 3
Injection of kainic acid into rat induced a limbic seizure and increased the activities of two protein kinases with Mrs of 42 kDa and 44 kDa in the hippocampus. These two protein kinases were identified as
MAP
kinases by an anti-
MAP kinase
antibody. These
MAP
kinases were phosphorylated at least at a tyrosine residue. The time course of the
MAP kinase
activation was roughly parallel with that of the seizure. These results indicate that the kainic acid-induced seizure induces
MAP kinase
activation in rat hippocampus.
...
PMID:Phosphorylation and activation of mitogen-activated protein kinase by kainic acid-induced seizure in rat hippocampus. 751 21
Stimulation of CHO cells with phorbol ester caused transient activation of
mitogen-activated protein kinase
(
MAP
-kinases with 42 and 44 kDa). A similar treatment of CHO cells which overexpress a massive amount of the alpha- or delta-isoform of protein kinase C (PKC) resulted in the prolonged activation of
MAP
-kinase and eventually in the appearance of mostly dikaryotic, sometimes tetrakaryotic cells. The results suggest that the delta-isoform, as well as the alpha-isoform, has a potential to cause
MAP kinase
activation. Unusual activation of the PKC/
MAP
-kinase pathway, however, may lead to abnormal cytokinesis.
...
PMID:The protein kinase C isoforms leading to MAP-kinase activation in CHO cells. 753 55
IL-11 is a multifunctional cytokine biologically related to IL-6, leukemia inhibitory factor (LIF), oncostatin M (OSM) and ciliary neurotrophic factor (CNTF). It has been shown that these cytokines can utilize common signal transducer, gp130. We have demonstrated that Jak tyrosine kinases,
MAP
kinases and pp90rsk are highly activated by IL-11 and related cytokines. In addition, we have identified pp90rsk as one of the H7 sensitive protein kinases critical for primary response gene expression induced by IL-11. Furthermore, activation of 3CH134 (a
MAP kinase
phosphatase) gene by IL-11 suggested that a
MAP kinase
phosphatase may be involved in IL-11-mediated signal transduction. Our data also suggested that tyrosine phosphorylation of Stat91 and related transcriptional factors is involved in IL-11 signaling but is not sufficient for the activation of primary response genes such as JunB, tis11, tis8 and
MAP kinase
phosphatase in mouse preadipocytes. The understanding of signal transduction pathways mediated by IL-11 and related cytokines may help to define the common and unique biological properties of these growth factors.
...
PMID:Interleukin (IL)-11--mediated signal transduction. 754 69
Protein phosphorylation has evolved as the most versatile posttranslational modification widely used by cells. Signal transduction pathways mediated by activation of
MAP
kinases and protein kinase C trigger the exit of cells from the quiscence (Go-->G1 transition). Indeed, binding of growth factors at the cell surface triggers their receptors, usually possessing a tyrosine kinase on the cytoplasmic side, to phosphorylate other molecules passing on the information sequentially to GRB2 protein, to p21ras, to c-Raf-1, to MAP kinase kinase, to
MAP kinase
, to p90rsk, to transcription factors. Activated PKC,
MAP kinase
, and pp90src can translocate to the nucleus where they phosphorylate a number of protein transcription regulators in a cell cycle-dependent manner or in response to cell stimulation for exit from quiescence. The cell cycle is mainly regulated by p34cdc2 or otherwise called cdc2 in association with cyclins B at G2/M and by Cdk2 in association with cyclins A, D1, and E at G1/S checkpoints; phosphorylation of histone H1 and lamins by cdc2 triggers chromosome assembly and nuclear envelope breakdown, respectively, as a prelude to mitosis. Cdc2 activities functioning as a G2/M regulator are controlled by its phosphorylation and dephosphorylation at Ser/Thr residues.
MAP
kinases might be the missing link in the chain connecting the Go to G1 transition with the cell cycle regulation, whereas phosphorylation of replication protein factors, retinoblastoma, and p53 might link the G1 to S transition with the control of DNA synthesis. A number of transcription factors are known to stimulate DNA replication, including p53, c-Myc, AP-1, Oct-1, T-antigen; the DNA binding activities of all these proteins and their interaction with other transcription factors are controlled by phosphorylation. The nuclear import of several proteins including NF kappa B, Dorsal, glucocorticoid receptor, ISGF3, rNFIL-6, T antigen, and the kinases PKC,
MAP
, and p90rsk, are dependent on their phosphorylation at specific sites. Histone phosphorylation stimulated at discrete stages of the cell cycle or in response to cAMP or other stimuli might induce profound changes in chromatin organization.
...
PMID:Phosphorylation of transcription factors and control of the cell cycle. 754 80
Olomoucine (2-(2-hydroxyethylamino)-6-benzylamino-9-methylpurine) has been recently described as a competitive inhibitor (ATP-binding site) of the cell cycle regulating p34cdc2/cyclin B, p33cdk2/cyclin A and p33cdk2/cyclin E kinases, the brain p33cdk5/p35 kinase and the
ERK1
/
MAP
-kinase. The unusual specificity of this compound towards cell cycle regulating enzymes suggests that it could inhibit certain steps of the cell cycle. The cellular effects of olomoucine were investigated in a large variety of plant and animal models. This compound inhibits the G1/S transition of unicellular algae (dinoflagellate and diatom). It blocks Fucus zygote cleavage and development of Laminaria gametophytes. Stimulated Petunia mesophyl protoplasts are arrested in G1 by olomoucine. By arresting cleavage it blocks the Laminaria gametophytes. Stimulated Petunia mesophyl protoplasts are arrested in G1 by olomoucine. By arresting cleavage it blocks the development of Calanus copepod larvae. It reversibly inhibits the early cleavages of Caenorhabditis elegans embryos and those of ascidian embryos. Olomoucine inhibits the serotonin-induced prophase/metaphase transition of clam oocytes; furthermore, it triggers the the release of these oocytes from their meiotic metaphase I arrest, and induces nuclei reformation. Olomoucine slows down the prophase/metaphase transition in cleaving sea urchin embryos, but does not affect the duration of the metaphase/anaphase and anaphase/telophase transitions. It also inhibits the prophase/metaphase transition of starfish oocytes triggered by various agonists. Xenopus oocyte maturation, the in vivo and in vitro phosphorylation of elongation factor EF-1 are inhibited by olomoucine. Mouse oocyte maturation is delayed by this compound, whereas parthenogenetic release from metaphase II arrest is facilitated. Growth of a variety of human cell lines (rhabdomyosarcoma cell lines Rh1, Rh18, Rh28 and Rh30; MCF-7, KB-3-1 and their adriamycin-resistant counterparts; National Cancer Institute 60 human tumor cell lines comprising nine tumor types) is inhibited by olomoucine. Cell cycle parameter analysis of the non-small cell lung cancer cell line MR65 shows that olomoucine affects G1 and S phase transits. Olomoucine inhibits DNA synthesis in interleukin-2-stimulated T lymphocytes (CTLL-2 cells) and triggers a G1 arrest similar to interleukin-2 deprivation. Both cdc2 and cdk2 kinases (immunoprecipitated from nocodazole- and hydroxyurea-treated CTLL-2 cells, respectively) are inhibited by olomoucine. Both yeast and Drosophila embryos were insensitive to olomoucine. Taken together the results of this Noah's Ark approach show that olomoucine arrests cells both at the G1/S and the G2/M boundaries, consistent with the hypothesis of a prevalent effect on the cdk2 and cdc2 kinases, respectively.
...
PMID:Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. 754 5
alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor channels play important roles in plasticity, neurotransmission, and neurotoxicity in the central nervous system. AMPA, but not N-methyl-D-aspartate (NMDA), receptor signaling in rat cortical neurons was found to involve a G-protein coupled to a protein kinase cascade. While both NMDA and AMPA activated
p42 mitogen-activated protein kinase
(
MAPK
) in neurons, only AMPA-induced
MAPK
was inhibited by pertussis toxin. AMPA, but not NMDA, caused an association of a G-protein beta subunit with a Ras, Raf kinase, and
MAP
/ERK kinase (MEK)-1 complex. The evidence indicates that AMPA triggers
MAPK
activation via a novel mechanism in which G-protein beta gamma dimers released from G alpha bind to a Ras protein complex causing the activation of Ras, Raf kinase, MEK-1, and finally
MAPK
.
...
PMID:alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, but not N-methyl-D-aspartate, activates mitogen-activated protein kinase through G-protein beta gamma subunits in rat cortical neurons. 755 6
The enzymatic activity of mitogen-activated protein kinases (
MAP
kinases) increases in response to agents acting on a variety of cell surface receptors, including receptors linked to heterotrimeric G proteins of the Gi and Gq family. Recently, it has been shown that stimulation of beta-adrenergic receptors, which are typical of those that act through Gs to activate adenylyl cyclases, potently activates
MAP
kinases in the heart, resulting in the hypertrophy of the cardiac muscle (Lazou, A., Bogoyevitch, M.A., Clerk, A., Fuller, S.J., Marshall, C.J., and Sudgen, P.H. (1994) Circ. Res. 75, 938-941). We have observed that exposure of COS-7 cells to a beta-adrenergic agonist, isoproterenol, raises intracellular levels of cAMP and effectively activates protein kinase A (PKA) and an epitope-tagged
MAP kinase
. However,
MAP kinase
stimulation by isoproterenol was neither mimicked by expression of an activated mutant of G alpha s, nor by treatment with PKA-stimulating agents. Moreover, pretreatment of COS-7 with a permeable cAMP analog, 8-Br-cAMP, markedly decreased
MAP kinase
activation by either isoproterenol or epidermal growth factor. Thus, in COS-7 cells cAMP and PKA do not appear to mediate
MAP kinase
activation by beta-adrenergic receptors. Signaling from beta-adrenergic receptors to
MAP kinase
was inhibited by transfection of a chimeric molecule consisting of the CD8 receptor and the carboxyl terminus of the beta-adrenergic receptor kinase, which includes the beta gamma-binding domain.
MAP kinase
activation by isoproterenol was not affected by depletion of protein kinase C, but it was completely abolished by expression of Ras-inhibiting molecules. We conclude that signaling from beta-adrenergic receptors to
MAP kinase
involves an activating signal mediated by beta gamma subunits acting on a Ras-dependent pathway and a G alpha s-induced inhibitory signal mediated by cAMP and PKA. The balance between these two opposing mechanisms of regulation would be expected to control the
MAP kinase
response to beta-adrenergic agonists as well as to other biologically active agents known to act on Gs coupled receptors, including a number of hormones, neurotransmitters, and lipid mediators.
...
PMID:Dual effect of beta-adrenergic receptors on mitogen-activated protein kinase. Evidence for a beta gamma-dependent activation and a G alpha s-cAMP-mediated inhibition. 755 65
When quiescent dog thyroid epithelial cells in primary culture are stimulated for 48 h with thyrotropin (TSH), forskolin acting through cAMP, or with cAMP-independent mitogens including epidermal growth factor (EGF), hepatocyte growth factor (HGF), and a tumor promoting phorbol ester (TPA), only 30-60% of cells progress through the cell cycle. A more general growth response requires the combination of EGF and TSH or forskolin. In this study we ask whether this intercellular heterogeneity in mitogen sensitivity could depend on a similar heterogeneity at early stages of the mitogenic stimulation process, i.e., at the levels of p42/p44
MAP kinase
nuclear translocation and c-Fos protein appearance. We used indirect immunofluorescence microscopy with photometric quantitation and corroborated data using Western blotting. We analyzed the double staining of c-Fos and p42/p44
MAP
kinases, since the nuclear translocation of these
MAP
kinases has been suggested as a key step for the stimulation of c-fos transcription. (i) EGF and HGF induced c-Fos accumulation and
MAP kinase
translocation in variable fractions of the cell population that corresponded to their relative potency as mitogens. c-Fos appearance and
MAP kinase
translocation poorly correlated in individual cells. Many cells accumulated c-Fos without any detectable p42/p44
MAP kinase
translocation. The heterogeneity of proliferative responses to EGF could be due to the lack of c-Fos or
MAP kinase
responsiveness of many cells. (ii) TPA induced c-Fos accumulation and
MAP kinase
translocation within the whole cell population, which did not explain the heterogeneity of the growth response to this factor and showed that these events are not sufficient to elicit DNA synthesis, (iii) TSH and forskolin induced a weak c-Fos accumulation in only a minority of cells but, as previously shown, no p42/p44
MAP kinase
phosphorylation and translocation. An important c-Fos expression was thus dispensable for the strong DNA synthesis stimulation exerted by cAMP-dependent mitogens. (iv) Forskolin potentiated the EGF effect on c-Fos expression but not on p42/p44
MAP kinase
phosphorylation and translocation. This reflected the fact that EGF induced c-Fos accumulation in 90% of cells in the presence of forskolin but in 30-50% of cells in its absence. This kind of potentiation, which specifically implies an increase in the fraction of responding cells, is termed "generalization" in the present study.(ABSTRACT TRUNCATED AT 400 WORDS)
...
PMID:Intercellular heterogeneity of early mitogenic events: cAMP generalizes the EGF effect on c-Fos protein appearance but not on MAP kinase phosphorylation and nuclear translocation in dog thyroid epithelial cells. 758 41
The mitogen-induced gene, DUSP2, encodes a nuclear protein, PAC1, that acts as a dual-specific protein phosphatase with stringent substrate specificity for
MAP kinase
.
MAP kinase
phosphorylation and consequent enzymatic activation is a central and often obligatory component in signal transduction initiated by growth factor stimulation or resulting from various types of oncogenic transformation. DUSP2 downregulates intracellular signal transduction through the dephosphorylation/inactivation of
MAP
kinases. To facilitate assessment of the possible role of DUSP2 in growth processes, the genomic structure and chromosomal location of the gene have been determined. DUSP2 has been localized to the pericentromeric region of human chromosome 2 (2p11.2-q11) by analysis of somatic cell hybrids, in situ chromosome hybridization, and genetic linkage analysis using a single-strand conformational polymorphism (SSCP) that has been identified in the 3' UTR of the gene. No consistent translocations or deletions at this chromosomal site have been reported in hematopoietic neoplasias or other tumors.
...
PMID:Genomic organization and chromosomal localization of the DUSP2 gene, encoding a MAP kinase phosphatase, to human 2p11.2-q11. 759 Jul 52
<< Previous
1
2
3
4
5
6
7
8
9
10
Next >>